(2S,3S)-methyl 2-[(tert-butoxycarbonyl)amino]-3-methoxybutanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,3S)-methyl 2-[(tert-butoxycarbonyl)amino]-3-methoxybutanoate
• 英文别名: methyl (2S,3S)-2-(tert-butoxycarbonylamino)-3-methoxybutanoate；methyl (2S,3S)-3-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate
• 化学式: C₁₁H₂₁NO₅
• 分子量: 247.291
• InChiKey: UTYNOLKQGKDHAV-YUMQZZPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S,3S)-methyl 2-[(tert-butoxycarbonyl)amino]-3-methoxybutanoate 在 lithium hydroxide monohydrate 、 水 作用下， 以 四氢呋喃 为溶剂， 生成 (2S,3S)-2-(tert-butoxycarbonylamino)-3-methoxybutanoic acid
  参考文献：
  名称：

  [EN] KCNT1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS DE KCNT1 ET PROCÉDÉS D'UTILISATION

  摘要：

  本发明部分涉及用于预防和/或治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况，以及基因（例如KCNT1）中的功能增强突变的化合物和组合物。本文还提供了治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况，以及基因如KCNT1中的功能增强突变的方法。

  公开号：

  WO2020227101A1
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 碳酸氢钠 、 silver(l) oxide 作用下， 以 甲醇 、 水 、 乙腈 为溶剂， 反应 64.0h， 生成 (2S,3S)-methyl 2-[(tert-butoxycarbonyl)amino]-3-methoxybutanoate
  参考文献：
  名称：

  [EN] KCNT1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS DE KCNT1 ET PROCÉDÉS D'UTILISATION

  摘要：

  本发明部分涉及用于预防和/或治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况，以及基因（例如KCNT1）中的功能增强突变的化合物和组合物。本文还提供了治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况，以及基因如KCNT1中的功能增强突变的方法。

  公开号：

  WO2020227101A1

文献信息

• Inhibitors of Memapsin 2 Cleavage for the Treatment of Alzheimer's Disease
  申请人：Purdue Research Foundation

  公开号：US20140066488A1

  公开（公告）日：2014-03-06

  Proteases such as memapsin 2 are important enzymes, playing roles in a variety of diseases including Alzheimer's Disease. The inventors have developed inhibitors of memapsin 2 and methods of use therefore in the treatment of disease.

  蛋白酶如膜蛋白酶2是重要的酶，发挥着在各种疾病中的作用，包括阿尔茨海默病。发明者已经开发了膜蛋白酶2的抑制剂以及在治疗疾病中使用的方法。
• Homophymine A, an Anti-HIV Cyclodepsipeptide from the Sponge <i>Homophymia</i> sp.
  作者：Angela Zampella、Valentina Sepe、Paolo Luciano、Filomena Bellotta、Maria Chiara Monti、Maria Valeria D’Auria、Trine Jepsen、Sylvain Petek、Marie-Thérèse Adeline、Olivier Laprévôte、Anne-Marie Aubertin、Cécile Debitus、Christiane Poupat、Alain Ahond

  DOI：10.1021/jo800583b

  日期：2008.7.1

  A new anti-HIV cyclodepsipeptide, homophymine A, was isolated from a New Caledonian collection of the marine sponge Homophymia sp. The structure of homophymine A was determined by interpretation of spectroscopic data, acid hydrolysis, and LC-MS analysis. Homophymine A contains 11 amino acid residues and an amide-linked 3-hydroxy-2,4,6-trimethyloctanoic acid moiety. Along with four D-, two L-, and one N-methyl arnino acids, it also contains four unusual amino acid residues: (2S,3S,4R)-3,4diMe-Gln, (2R,3R,4S)-4-amino-2,3-dihydroxy-1,7-heptandioic acid, L-ThrOMe, and (2R,3R,4R)-2-amino3-hydroxy-4,5-dimethylhexanoic acid. In a cell-based XTT assay, homophymine A exhibited cytoprotective activity against HIV-1 infection with a IC50 of 75 nM.
• Minutissamides E–L, antiproliferative cyclic lipodecapeptides from the cultured freshwater cyanobacterium cf. Anabaena sp.
  作者：Hahk-Soo Kang、Megan Sturdy、Aleksej Krunic、Hyunjung Kim、Qi Shen、Steven M. Swanson、Jimmy Orjala

  DOI：10.1016/j.bmc.2012.08.017

  日期：2012.10

  The extract of UIC 10035, a strain obtained from a sample collected near the town of Homestead, South Florida, showed antiproliferative activity against MDA-MB-435 cells. Bioassay-guided fractionation led to the isolation of a series of cyclic lipodecapeptides, named minutissamides E-L (1-8). The planar structures were determined by analysis of HRESIMS, tandem MS, and 1D and 2D NMR data, and the stereo-configurations were assigned by LC-MS analysis of the Marfey's derivatives after acid hydrolysis. Minutissamides E-L (1-8) exhibited antiproliferative activity against MDA-MB-435 cells with IC50 values ranging between 1 and 10 mu M. The structures of minutissamides E-L (1-8) were closely related with those of the previously reported lipopeptides, puwainaphycins A-E and minutissamides A-D, characterized by the presence of a lipophilic beta-amino acid and three non-standard amino acids NMeAsn, OMeThr and Dhb (alpha,beta-dehydro-alpha-aminobutyric acid). The strain UIC 10035 was designated as cf. Anabaena sp. on the basis of morphological and 16S rRNA gene sequence analyses. (C) 2012 Elsevier Ltd. All rights reserved.
• Structure-Based Design of Highly Selective β-Secretase Inhibitors: Synthesis, Biological Evaluation, and Protein–Ligand X-ray Crystal Structure
  作者：Arun K. Ghosh、Kalapala Venkateswara Rao、Navnath D. Yadav、David D. Anderson、Navnath Gavande、Xiangping Huang、Simon Terzyan、Jordan Tang

  DOI：10.1021/jm3008823

  日期：2012.11.8

  The structure-based design, synthesis, and X-ray structure of protein-ligand complexes of exceptionally potent and selective beta-secretase inhibitors are described. The inhibitors are designed specifically to interact with S-1' active site residues to provide selectivity over memapsin 1 and cathepsin D. Inhibitor 5 has exhibited exceedingly potent inhibitory activity (K-i = 17 pM) and high selectivity over BACE 2 (>7000-fold) and cathepsin D (>250000-fold). A protein ligand crystal structure revealed important molecular insight into these selectivities. These interactions may serve as an important guide to design selectivity over the physiologically important aspartic acid proteases.
• KCNT1 INHIBITORS AND METHODS OF USE
  申请人：Praxis Precision Medicines, Inc.

  公开号：US20220259193A1

  公开（公告）日：2022-08-18

  The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.